Imolast (Timolol Maleate, Latanoprost)

Timolol maleate is a non‑selective β‑adrenergic antagonist that blocks β‑receptors in the ciliary body. This inhibition reduces the production of aqueous humor, leading to a decrease in intra‑ocular pressure, which is essential in managing glaucoma.

The dosing regimen for Imolast is determined by the prescribing clinician based on individual patient needs. Typically, one drop is instilled in the affected eye(s) once daily, but the exact frequency and duration are set by the healthcare professional.

Safety data for Imolast in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Imolast, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imolast combines a beta‑blocker (timolol) and a prostaglandin analog (latanoprost) in a single formulation, offering dual mechanisms of action. Compared with monotherapy agents, this combination can achieve greater intra‑ocular pressure reduction with a single daily drop, potentially improving adherence.

Imolast should be stored at room temperature, below 25 °C. Keep the bottle tightly closed, protect it from direct light and moisture, and do not freeze. Discard any solution that appears discolored or contains particles.

Imolast is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and instill one drop into the conjunctival sac. Close the eye gently for a few minutes and avoid touching the tip of the bottle to any surface.

Serious risks include significant ocular inflammation, severe allergic reactions, permanent changes in iris color, worsening of glaucoma despite therapy, and systemic β‑blocker effects such as bradycardia, hypotension, or bronchospasm, especially in patients with respiratory disease.

Imolast is contraindicated in patients with known hypersensitivity to timolol, latanoprost, or any excipients, as well as those with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, or advanced heart block. Caution is also advised for individuals with active ocular infections.